Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

2.

How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs

3.

A Lot Can Be Said About You by Including Yourself in Photos.

4.

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

5.

Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot